Document Detail

Increase in response rate by prolonged treatment with neoadjuvant letrozole.
MedLine Citation:
PMID:  18264759     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The aim of this study was to investigate the potential benefits of prolonged treatment with neoadjuvant letrozole. PATIENTS AND METHODS: About 182 consecutive patients have been treated in Edinburgh with neoadjuvant letrozole for 3 months or longer and 63 patients have continued on letrozole beyond 3 months. Outcomes are reported. RESULTS: Of the 63 patients who continued on letrozole, 38 patients took letrozole for more than 1 year and 23 took letrozole for more than 24 months. The median reduction in clinical volume in the first 3 months in these 63 patients was 52%. Similar reductions in median clinical volume were seen between three to 6 months (50%), 6-12 months and 12-24 months (medians 37 and 33%, respectively). At 3 months 69.8% of the 182 patients had a partial or complete response. The response rate increased to 83.5% with prolonged letrozole treatment. Continuing letrozole beyond 3 months increased the number of women who initially required mastectomy or had locally advanced breast cancer who were subsequently suitable for breast conserving surgery from 60% (81/134) at 3 months to 72% (96/134). Thirty-three women remain on letrozole alone (man age at diagnosis 83 years) and at 3 years the median time to treatment failure has not been reached. CONCLUSION: Continuing letrozole in responding patients beyond 3-4 months achieves further clinical reduction in tumour size. For elderly women with a short life expectancy letrozole alone may provide long-term disease control.
J Michael Dixon; Lorna Renshaw; E Jane Macaskill; Oliver Young; Juliette Murray; David Cameron; Gillian R Kerr; Dean B Evans; William R Miller
Related Documents :
9734449 - Open rhinoplasty: columellar scar analysis in an arabian population.
9773999 - Breast reconstruction by means of innervated rectus abdominis myocutaneous flap.
25093649 - Subaxial sagittal alignment after atlantoaxial fixation techniques.
21821499 - Clinical significance of intestinal type fatty acid binding protein in patients undergo...
24806259 - The effects of osteoporosis and disc degeneration on vertebral cartilage endplate lesio...
8881779 - A review of 120 becker permanent tissue expanders in reconstruction of the breast.
24736769 - A novel running mechanic's class changes kinematics but not running economy.
8884859 - Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operatio...
18082489 - Inflammatory responses after intracoronary injection of autologous mononuclear bone mar...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-02-09
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  113     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-02-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  145-51     Citation Subset:  IM    
Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*,  pathology,  surgery*
Combined Modality Therapy
Disease Progression
Drug Administration Schedule
Life Expectancy
Mastectomy, Segmental
Neoadjuvant Therapy
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Racial and ethnic differences in mammography use among U.S. women younger than age 40.
Next Document:  Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status:...